BlackRock Fund Advisors’s Larimar Therapeutics LRMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$2.32M Sell
60,774
-22,998
-27% -$933K ﹤0.01% 3137
2016
Q3
$3.33M Buy
83,772
+6,308
+8% +$286K ﹤0.01% 3034
2016
Q2
$5.57M Buy
77,464
+11,973
+18% +$946K ﹤0.01% 2733
2016
Q1
$5.25M Buy
65,491
+2,619
+4% +$207K ﹤0.01% 2721
2015
Q4
$4.75M Sell
62,872
-4,996
-7% -$803K ﹤0.01% 2864
2015
Q3
$26M Buy
67,868
+2,772
+4% +$1.25M 0.01% 1829
2015
Q2
$27.1M Buy
65,096
+19,188
+42% +$8.03M 0.01% 1924
2015
Q1
$21.8M Buy
45,908
+7,737
+20% +$3.67M 0.01% 2022
2014
Q4
$14.1M Buy
38,171
+24,012
+170% +$6.19M ﹤0.01% 2249
2014
Q3
$3.34M Buy
+14,159
New +$3.21M ﹤0.01% 2974

Other funds holding LRMR

BlackRock Fund Advisors's LRMR Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Larimar Therapeutics (LRMR) stake by 27% in Q4 2016, selling an estimated $933K and leaving 60,774 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

BlackRock Fund Advisors first reported a position in LRMR in Q3 2014 and has held it in 10 quarters since. The position peaked at $27.1M in Q2 2015. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

  • BlackRock Fund Advisors held 60,774 shares of Larimar Therapeutics worth $2.32M as of Q4 2016.
  • BlackRock Fund Advisors sold 22,998 Larimar Therapeutics shares in Q4 2016, an estimated $933K.
  • Larimar Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3137 holding.
  • BlackRock Fund Advisors first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 10 quarters since.
  • BlackRock Fund Advisors's Larimar Therapeutics position peaked at $27.1M in Q2 2015.
  • 81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.